The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective

Campbell JD, Spackman DE, Sullivan SD

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details
Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy: European Journal of Allergy and Clinical Immunology 2010; 65(9) : 1141-1148

PubMedID
20148804

DOI
10.1111/j.1398-9995.2010.02336.x

Indexing Status
Subject indexing assigned by NLM

MeSH
Adrenal Cortex Hormones /economics /therapeutic use; Antibodies, Anti-Idiotypic /economics /therapeutic use; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Asthma /drug therapy /economics /mortality /physiopathology; Chronic Disease; Cost-Benefit Analysis; Hospitalization /statistics & numerical data; Humans; Markov Chains; Models, Economic; Omalizumab; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Treatment Outcome; United States

AccessionNumber
22010001491

Date bibliographic record published
09/03/2011